作者:贝壳社历经4次递表,拨康视云 (02592.HK) 近日正式港股上市。01破局拨康视云深耕眼科疗法领域,专注于创新疗法的发现、开发与商业化。其研发管线广泛,涵盖了八种候选药物,彰显了其在眼科领域的深厚布局与前瞻视野。此次募资金额将主要用于支持CBT-001正在进行的Ⅲ期临床试验。在此之前,拨康视云曾四次向港交所递交上市申请,最终成功上市。经营层面面临的挑战,尤其是持续的财务亏损及收入匮乏,...
Source Link作者:贝壳社历经4次递表,拨康视云 (02592.HK) 近日正式港股上市。01破局拨康视云深耕眼科疗法领域,专注于创新疗法的发现、开发与商业化。其研发管线广泛,涵盖了八种候选药物,彰显了其在眼科领域的深厚布局与前瞻视野。此次募资金额将主要用于支持CBT-001正在进行的Ⅲ期临床试验。在此之前,拨康视云曾四次向港交所递交上市申请,最终成功上市。经营层面面临的挑战,尤其是持续的财务亏损及收入匮乏,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.